What Gingival Overgrowth Is and What It Looks Like
Gingival overgrowth (also called gingival hyperplasia or gingival enlargement) is an abnormal increase in the size of the gum tissue that causes it to cover more of the tooth surface than normal. In mild cases, the gum tissue grows slightly beyond the natural gum margin, rounding the papillae (the triangular tissue between teeth) into bulbous, bead-like projections. In severe cases, the tissue can cover most or all of the visible crown of the tooth, making it difficult to speak clearly, chew effectively, and maintain basic hygiene.
The tissue itself may feel firm and fibrous (particularly in drug-induced cases) or soft and edematous. Its color ranges from normal pink to inflamed red, depending on how much secondary infection and plaque accumulation is present. One of the insidious aspects of gingival overgrowth is that it creates pseudopockets: the gum tissue is elevated, creating apparent pocket depth on a probe that is not actually a measure of bone destruction but of tissue overgrowth. Real bone loss can be present simultaneously, but measuring it requires distinguishing true attachment loss from pseudopocket depth on careful examination.
Gingival overgrowth can affect a single localized area (as in a pregnancy epulis, a localized overgrowth near a specific tooth), multiple segments of the mouth (as in many drug-induced cases), or the entire dentition. The distribution often provides clues to the cause. Drug-induced cases tend to be more severe in the anterior teeth and in areas with pre-existing plaque accumulation.
Drug-Induced Overgrowth: Calcium Channel Blockers
Calcium channel blockers, a class of medications used to treat high blood pressure, angina, and certain arrhythmias, are among the most common causes of drug-induced gingival overgrowth. The most commonly implicated agent is nifedipine, with reported prevalence of gingival overgrowth around thirty to fifty percent of patients taking it. Amlodipine (Norvasc), the most commonly prescribed calcium channel blocker in the United States, causes overgrowth less frequently than nifedipine but is prescribed so widely that it accounts for a significant number of cases in clinical practice. Diltiazem, felodipine, and verapamil are also implicated.
The biological mechanism involves the drug's effect on fibroblasts, the cells responsible for producing and remodeling the collagen matrix of gum tissue. Calcium channel blockers appear to reduce the activity of collagenase enzymes that would normally break down excess collagen, leading to net accumulation of collagen in the gum tissue. The result is a firm, fibrous enlargement rather than a soft, inflammatory swelling. Interestingly, not all patients on these medications develop overgrowth, suggesting that individual genetic variation in fibroblast behavior determines susceptibility.
Plaque accumulation significantly amplifies drug-induced overgrowth. Patients with poor oral hygiene develop more pronounced overgrowth on these medications than patients with excellent hygiene. This has led to recommendations that patients who are starting a calcium channel blocker undergo dental prophylaxis and receive enhanced oral hygiene counseling at the time the medication is initiated, not after overgrowth is already established. If overgrowth does develop, consultation with the prescribing physician about substituting an alternative antihypertensive that does not cause this effect is appropriate.
Drug-Induced Overgrowth: Phenytoin and Cyclosporine
Phenytoin (Dilantin), an anticonvulsant medication used for epilepsy, was the first drug recognized to cause gingival overgrowth, with the association identified in the 1930s. Overgrowth occurs in approximately fifty percent of patients taking phenytoin, making it one of the most common adverse effects of the drug. The tissue enlargement typically begins in the interdental papillae (the gum tissue between teeth) within the first three months of therapy, and can progress to nearly cover the teeth in severe cases.
Phenytoin-induced overgrowth has the same fibroblast-related mechanism as calcium channel blocker-induced overgrowth, and plaque accumulation similarly amplifies it. For patients on phenytoin, rigorous oral hygiene and regular professional cleaning can minimize the extent of overgrowth but may not prevent it entirely. If phenytoin cannot be substituted with an alternative anticonvulsant and the overgrowth becomes severe enough to interfere with function, surgical treatment is required with the expectation that tissue may re-enlarge if the medication is continued.
Cyclosporine, an immunosuppressant used to prevent organ transplant rejection and to treat autoimmune conditions, causes gingival overgrowth in twenty-five to thirty percent of patients. The mechanism appears to involve both direct effects on fibroblasts and indirect effects through drug interactions with other transplant medications. Transplant patients often take both cyclosporine and a calcium channel blocker (commonly used to manage the hypertension that cyclosporine can cause), and the combination produces more severe overgrowth than either drug alone. Tacrolimus, an alternative immunosuppressant with a lower rate of gingival overgrowth, is sometimes substituted where clinically appropriate.
Idiopathic and Hereditary Gingival Fibromatosis
Not all gingival overgrowth is drug-induced. Hereditary gingival fibromatosis (HGF) is a rare condition, affecting roughly 1 in 175,000 people, in which gum tissue enlarges progressively without an associated medication. HGF can be inherited in an autosomal dominant or autosomal recessive pattern. The tissue enlargement is typically firm and fibrous, normal in color, and not necessarily inflammatory. It can begin in childhood, sometimes coinciding with the eruption of permanent teeth, and may become severe enough to completely bury the teeth within the tissue.
The genetic basis of HGF has been partially characterized. Mutations in the SOS1 gene (which encodes a guanine nucleotide exchange factor) have been identified in some families, and linkage to chromosome 2p has been found in others. However, the genetic cause in many families remains unknown. Treatment is surgical, but recurrence after surgery is the rule rather than the exception if the genetic drive for tissue overgrowth is not addressed. For patients with HGF, maintaining as much as possible through hygiene and staged surgical treatment is the long-term management strategy.
Localized gingival overgrowth at a single site can also occur as a response to chronic local irritation, a condition sometimes called a peripheral ossifying fibroma, pyogenic granuloma, or irritation fibroma depending on the tissue characteristics. These localized growths typically present as painless, sometimes pedunculated (stalk-attached) lumps on the gum. A bite wing that shows a calculus deposit, a rough crown margin, or a root tip beneath a localized overgrowth often explains the irritant. Treatment involves removing the growth and addressing the irritant source.
Treatment: When Surgery Is Needed
Nonsurgical treatment of gingival overgrowth starts with optimizing home care and removing all plaque and calculus through professional cleaning. For drug-induced cases, eliminating the causative medication (when medically feasible) leads to partial or complete resolution in some patients over several weeks to months. However, resolution is not guaranteed, and in many cases with established overgrowth the tissue does not return to normal size even after medication change. Professional cleaning and improved hygiene can reduce the inflammatory component of the enlargement but typically cannot reverse the fibrous component.
Surgical treatment is called gingivectomy: the removal of the excess gum tissue to re-expose the tooth crown and restore a normal gum margin. This is done with a scalpel, electrosurgery, or laser depending on the extent of the overgrowth and the clinician's tools. For extensive overgrowth involving many teeth, the procedure may be staged across multiple appointments. The surgery is performed under local anesthesia with sedation available for anxious patients.
When overgrowth has deepened pockets to the point of true bone loss, surgical treatment may need to combine gingivectomy with periodontal flap surgery to address the bone component simultaneously. Postoperative healing typically involves soreness and swelling for one to two weeks and a modified diet during this period. The risk with surgically treated drug-induced cases is recurrence: if the causative medication continues and oral hygiene is not maintained, the overgrowth returns, often within six to twelve months. This makes surgical treatment in these patients a recurring commitment rather than a one-time fix.
Talking to Your Doctor and Dentist About Your Medications
If you are taking a medication associated with gingival overgrowth and notice your gum tissue enlarging or your gums appearing to cover more of your teeth, mention it at your next dental visit before it becomes severe. Early-stage overgrowth is easier to manage non-surgically than established fibrous tissue. Your dentist can document the extent and distribution of the overgrowth, intensify the cleaning schedule, and provide a letter to your physician describing the clinical finding if a medication substitution discussion is warranted.
The decision to substitute a medication is always the prescribing physician's, not the dentist's. But dentists can provide the clinical information that makes that conversation possible. For antihypertensive medications, many alternatives to nifedipine are available with equivalent blood pressure control and lower rates of gingival overgrowth. For anticonvulsants, substitution may be more complex if phenytoin is the most effective agent for a patient's seizure type. For immunosuppressants in transplant patients, the transplant team must weigh the immune risks of substitution against the oral complications.
Before starting any medication known to cause gingival overgrowth, getting your gums into the best possible baseline health is the most protective step you can take. Inflammation amplifies drug-induced overgrowth significantly. A thorough cleaning and a period of improved hygiene before starting the medication can meaningfully reduce the likelihood and severity of overgrowth during the course of treatment.
Frequently asked questions
Calcium channel blockers as a class are the most commonly implicated blood pressure medications. Nifedipine has the highest reported rate (thirty to fifty percent of patients). Amlodipine (Norvasc) and diltiazem have lower rates but are very widely prescribed. Verapamil and felodipine are also associated. ACE inhibitors, ARBs, beta-blockers, and diuretics used for blood pressure do not typically cause gingival overgrowth and may be appropriate alternatives if a substitution is medically feasible.
In many patients with early or moderate drug-induced overgrowth, the tissue partially or fully regresses after the medication is stopped, typically over several weeks to months. In cases with established, fibrous overgrowth present for a long time, the tissue does not always fully regress even after the drug is removed, and surgery may still be needed. The sooner the medication is addressed after overgrowth begins, the better the chances of non-surgical resolution.
Drug-induced fibrous overgrowth does not resolve on its own while the causative medication continues. Better oral hygiene can reduce the inflammatory component and may slow progression, but the underlying fibrous enlargement driven by fibroblast activity requires either medication change or surgical treatment. Localized pregnancy-related overgrowth (pregnancy epulis) often resolves spontaneously after delivery.
Drug-induced fibrous overgrowth is usually not painful in itself. If the overgrown tissue develops secondary infection from trapped plaque and bacteria in the pseudopockets it creates, that can cause discomfort, bleeding, and bad breath. The main functional complaints are cosmetic concerns about the appearance of the teeth, difficulty cleaning, and occasionally difficulty chewing or speaking in severe cases.
Diagnosis is clinical: your dentist examines the tissue, measures pocket depths, and reviews your medication list. In cases where the cause is unclear or where a localized growth looks unusual, a biopsy may be sent to an oral pathologist to rule out a neoplastic process. Most drug-induced and hereditary overgrowth has characteristic appearances, and biopsy is not required for routine cases once the medication history is established.
Yes. Children with epilepsy on phenytoin are at risk for drug-induced overgrowth. Hereditary gingival fibromatosis can manifest in childhood, sometimes appearing when the permanent teeth erupt. Localized inflammatory growths can also occur in children in response to local irritants. Any unusual gum growth in a child should be evaluated by a dentist to determine the cause.
Questions about your teeth?
We verify your PPO coverage before your visit, provide a written estimate before any treatment is scheduled, and explain the structural reasoning behind every recommendation in plain English.